A leading global innovator in medical imaging, Qure.ai, has received pivotal 510(k) FDA approval for an AI-powered chest CT solution called qCT LN Quant to help radiologists and pulmonologists quantify lung nodules.
The FDA clearance allows medical specialists to use the technology to analyze lung nodules on non-contrast chest CT scans and monitor progression by tracking the volumetric growth of the nodules.
The company has integrated the newly approved technology into its AI-powered lung cancer care network in the United States to help identify, precisely measure, manage, and monitor lung health.
Qure.ai’s new tools will support the early detection of lung cancers, enabling clinicians to provide early treatments and leading to improved patient outcomes.
Key Features of Qure.ai’s Lung Health Solution
Qure.ai’s lung health technology solutions leverage artificial intelligence and advanced algorithms to classify radiology images, diagnose diseases, and highlight abnormalities that could go unidentified. This helps clinicians to highlight abnormalities in radiology images and diagnose diseases more accurately.
The company’s AI-powered platform consists of three major components.
qXR LN: Advanced AI tool for early detection and localizing lung nodules on the chest X-rays. This extends clinicians’ abilities to detect lung cancers beyond traditional CT-based techniques.
qTrack: A multi-modality lung-based nodule management platform. It integrates flawlessly with hospitals’ Electronic Medical Records (EMRs), allowing clinicians to quickly find and report lung cancer cases, collaborate with other health professionals, and prioritize patient cases.
qCT LN Quant: Features advanced measuring capabilities for quantitative characterization of lung nodules, advanced imaging decision support, and Reimbursement Eligibility capabilities, offering critical support to clinicians.
Qure.ai’s solutions are globally accepted. The company’s AI solutions have been deployed in over 3,000 sites in over 90 countries.